state
antileishmani
chemotherapi
strongli
compromis
emerg
drugresist
leishmania
evolut
drugresist
phenotyp
link
parasit
intrins
genom
instabl
frequent
gene
chromosom
amplif
caus
fit
gain
directli
select
environment
factor
includ
presenc
antileishmani
drug
thu
even
though
uniqu
eukaryot
biolog
leishmania
depend
parasitespecif
virul
factor
provid
valid
opportun
chemotherapeut
intervent
strategi
target
parasit
direct
fashion
like
prone
select
resist
review
current
state
antileishmani
chemotherapi
discuss
limit
ongo
drug
discoveri
effort
final
propos
new
strategi
target
leishmania
viabil
indirectli
via
mechan
hostparasit
interact
includ
parasitereleas
ectokinas
host
epigenet
regul
modul
host
cell
signal
transcript
regul
respect
establish
permiss
condit
intracellular
leishmania
surviv
leishmania
evolv
mechan
subvert
innat
adapt
immun
respons
caus
immun
dysregul
patholog
characterist
cl
vl
ultim
allow
parasit
prolifer
persist
infect
insid
mammalian
host
surprisingli
even
though
well
establish
leishmania
reprogram
host
cell
subvert
immun
respons
meet
nutrit
metabol
need
intracellular
parasit
surviv
prolifer
littl
effort
exploit
crucial
effect
parasit
host
cell
antiparasit
drug
discoveri
review
current
literatur
antileishmani
therapi
leishmania
hostpathogen
interact
discuss
novel
strategi
target
host
cell
rather
parasit
biolog
drug
discoverya
strategi
like
refractori
emerg
drugresist
parasit
recent
strategi
replac
antimoni
firstlin
treatment
circumv
limit
respect
toxic
drug
resist
larg
reli
repurpos
exist
drug
includ
antifung
drug
amphotericin
b
offpat
antibiot
paromomycin
oral
anticanc
drug
miltefosin
antimalari
drug
sitamaquin
shown
effici
treat
leishmanias
despit
success
repurpos
strategi
therapi
import
limit
miltefosin
teratogen
provok
acut
gastrointestin
side
effect
length
treatment
sever
week
caus
poor
treatment
complianc
risk
relaps
convent
amphotericin
b
deoxychol
nephrotox
also
costli
store
high
temperatur
render
unafford
countri
paromomycin
need
long
parenter
regimen
involv
qualifi
personnel
hospit
addit
depend
leishmania
speci
geograph
area
parasit
respons
drug
vari
substanti
exampl
cure
rate
paromomycin
treatment
vl
rang
sudanes
ethiopian
patient
respect
relaps
occur
postkalaazar
dermal
leishmaniasi
appear
even
month
fig
differ
aspect
macrophageleishmania
interact
leishmania
respond
intramacrophag
environ
adapt
differenti
left
panel
hijack
vital
macrophag
function
via
releas
parasit
ectoprotein
ectokinas
casein
kinas
isoform
affect
host
defens
mechan
caus
immun
subvers
middl
panel
modul
host
metabol
pathway
promot
parasit
growth
right
panel
leishmanias
neglect
diseas
prevail
tropic
subtrop
area
recent
report
indic
million
peopl
highburden
countri
million
peopl
highburden
countri
risk
cutan
leishmaniasi
cl
viscer
leishmaniasi
vl
respect
incid
human
leishmanias
show
import
increas
last
decad
due
multipl
factor
includ
fail
prevent
therapeut
measur
human
migrat
caus
conflict
polit
instabl
global
warm
emerg
drugresist
parasit
develop
countri
causal
agent
leishmanias
protozoan
parasit
leishmania
genu
belong
trypanosomatida
famili
parasit
life
cycl
promastigot
form
transmit
bloodfeed
sandfli
vertebr
host
develop
diseasecaus
amastigot
form
insid
host
phagocyt
control
intracellular
leishmania
develop
reli
primarili
chemotherapi
also
abil
parasit
host
mount
effici
immun
respons
macrophag
play
key
role
antiparasit
resist
also
immunopatholog
sentinel
cell
particip
directli
contain
clearanc
leishmania
innat
immun
function
stimul
protect
respons
intracellular
leishmania
host
cell
coevolv
intric
dynam
interact
fig
end
therapi
drawback
togeth
high
attrit
rate
observ
leishmanias
drug
discoveri
pipelin
caus
recent
shift
discoveri
new
drug
use
combin
therapi
involv
drug
lower
dosag
shorter
treatment
durat
believ
overcom
major
handicap
current
drug
ie
toxic
emerg
drugresist
parasit
import
limit
current
antileishmani
drug
howev
repres
treatment
failur
emerg
drugresist
parasit
bihar
state
india
effici
antimoni
therapi
fell
certain
hyperendem
area
due
presenc
drugresist
strain
leishmania
infantum
strain
isol
patient
suffer
variou
relaps
receiv
multipl
antimoni
amphotericin
b
treatment
shown
resist
drug
suggest
even
combin
therapi
may
limit
use
current
effort
toward
antileishmani
drug
discoveri
larg
reli
identif
target
molecul
present
signific
structur
andor
function
differ
mammalian
ortholog
implic
biochem
metabol
pathway
essenti
parasit
viabil
infect
follow
rational
number
potenti
target
candid
identifi
review
implic
larg
varieti
biolog
function
tabl
possibl
select
inhibit
proteasom
pathogen
trypanosomatid
ie
leishmania
spp
trypanosoma
cruzi
brucei
without
interf
mammalian
ortholog
pathway
hold
great
promis
discov
novel
treatment
broad
applic
import
neglect
tropic
diseas
ntd
panantikinetoplastid
drug
may
motiv
big
pharma
engag
ntd
drug
develop
increas
potenti
econom
return
despit
success
biochem
pharmacolog
genet
approach
valid
larg
number
leishmania
molecul
potenti
drug
target
new
drug
directli
target
parasit
includ
pankinetoplastid
therapi
like
short
therapeut
use
given
capac
leishmania
rapidli
evolv
toward
drugresist
phenotyp
partli
link
remark
genom
plastic
well
establish
leishmania
escap
drug
action
modul
gene
content
variou
mechan
includ
gene
tandem
duplic
delet
extrachromosom
amplif
reli
homolog
recombin
via
interspers
repeat
sequenc
element
absenc
transcript
regul
leishmania
often
resort
chromosom
amplif
mean
modul
gene
express
overrid
drug
pressur
adapt
chang
environ
likewis
mutat
delet
transport
gene
code
aquaglyceroporin
miltefosin
transport
accessori
protein
link
drug
resist
follow
therefor
propos
hostdirect
therapeut
strategi
new
venu
antileishmani
drug
discoveri
discuss
may
refractori
emerg
drug
resist
leishmaniamacrophag
interact
provid
excel
exampl
coevolut
promot
parasit
surviv
caus
diseas
conceiv
interf
process
repres
promis
new
strategi
antileishmani
intervent
follow
explor
possibl
target
macrophageleishmania
interact
review
current
literatur
host
cell
pathway
modul
intracellular
leishmania
macrophag
elimin
pathogen
microorgan
directli
via
nitric
oxid
reactiv
oxygen
speci
ro
indirectli
via
product
proinflammatori
cytokin
initi
antimicrobi
respons
leishmania
evad
subvert
host
cell
function
use
parasit
protein
glycolipid
effector
either
express
parasit
surfac
releas
cytoplasm
target
host
cell
signal
process
addit
leishmania
interfer
antigenpresent
capac
host
cell
multipl
mechan
implic
chang
abund
costimulatori
molecul
one
strike
featur
molecular
dialogu
leishmania
host
cell
increas
life
span
observ
parasiteinfect
macrophag
sinc
semin
studi
moor
matlashewski
suggest
leishmaniadepend
inhibit
host
cell
apoptosi
observ
confirm
variou
report
recent
report
studi
antiapoptot
effect
observ
vl
mous
model
propos
molecular
mechan
involv
leishmaniacpg
motif
host
myeloid
cell
leukemia
factor
camp
respons
element
bind
protein
creb
transcript
factor
auxotrophi
intracellular
leishmania
amastigot
development
stage
variou
essenti
nutrient
render
parasit
depend
upon
host
resourc
growth
mammalian
colon
therefor
surpris
impact
leishmania
infect
host
cell
transcriptom
translat
import
metabol
chang
fuel
parasit
intracellular
growth
inde
variou
report
demonstr
upregul
gene
code
key
molecul
involv
sterol
fatti
acid
metabol
earli
phase
infect
activ
multipl
intracellular
parasit
transcript
studi
support
proteom
find
demonstr
establish
leishmaniaspecif
macrophag
protein
express
profil
singular
featur
relat
major
metabol
pathway
togeth
data
confirm
leishmania
turn
host
cell
metabol
factori
ensur
intracellular
amastigot
growth
conceiv
metabol
depend
parasit
host
cell
may
open
new
venu
elimin
intracellular
leishmania
exampl
pharmacolog
restor
normal
macrophag
metabol
function
may
caus
parasit
death
starvat
target
host
antimicrobi
therapi
recogn
new
fertil
venu
treat
viral
bacteri
fungal
diseas
provid
advantag
dramat
increas
genet
barrier
drug
resist
hostdirect
therapi
larg
depend
either
drug
develop
noncommunic
diseas
show
good
safeti
profil
variou
form
immunotherapeut
intervent
possibl
adopt
strategi
leishmania
support
report
antileishmani
effect
imiquimod
act
tolllik
receptor
tlr
agonist
compound
naloxonazin
kill
intracellular
leishmania
target
host
cell
vatpas
follow
propos
parasitereleas
ectoprotein
affect
host
cell
signal
transduct
tran
host
histonemodifi
enzym
may
subvert
intracellular
leishmania
possibl
target
discoveri
hostdirect
drug
candid
tabl
although
impact
intracellular
leishmania
host
cell
immun
signal
pathogenesi
recogn
littl
inform
avail
parasit
signal
protein
particularli
releas
protein
kinas
involv
modul
host
cell
signal
import
releas
kinas
surviv
intracellular
parasit
well
illustr
member
toxoplasma
rop
kinas
famili
phosphoryl
activ
thu
mimick
antiinflammatori
signal
transduct
likewis
member
plasmodium
fik
kinas
protein
famili
export
erythrocyt
cytoplasm
shortli
infect
implic
remodel
host
cell
membran
cytoskeleton
like
impact
cytoadhes
contrast
role
leishmania
ectokinas
intracellular
infect
studi
detail
studi
secretom
exosom
proteom
l
donovani
promastigot
identifi
put
ectoprotein
includ
secret
exosom
kinas
major
involv
biochem
process
glycolyt
pathway
nucleotid
synthesi
suggest
import
effect
host
cell
metabol
signal
kinas
identifi
ie
mitogenactiv
protein
kinas
casein
kinas
isoform
function
link
infect
host
cell
immun
subvers
thu
describ
serinethreonin
protein
kinas
attract
consider
interest
put
drug
target
known
inhibitor
shown
block
growth
extracellular
leishmania
vitro
cultur
intracellular
parasit
establish
primari
murin
macrophag
leishmania
highli
conserv
kinas
ident
human
ortholog
suggest
evolut
kinas
driven
interact
host
cell
substrat
also
conserv
kinas
across
leishmania
speci
ident
support
notion
evolut
may
uncoupl
speciesspecif
constraint
driven
interact
host
protein
intracellular
infect
addit
directli
phosphoryl
host
substrat
human
complement
compon
human
receptor
attenu
cellular
respons
vitro
kinas
thu
like
impact
host
cell
signal
metabol
establish
permiss
condit
intracellular
leishmania
surviv
target
parasitereleas
transact
signal
factor
constitut
interest
novel
approach
develop
antileishmani
reason
first
kinas
inhibitor
prime
candid
treat
variou
human
patholog
includ
cancer
diabet
inflamm
thu
drugdiscoveri
effort
direct
target
leishmaniareleas
kinas
benefit
avail
dedic
librari
alreadi
well
character
second
conceiv
inhibitor
target
leishmaniareleas
kinas
affect
host
may
refractori
develop
drug
resist
final
mutat
kinas
may
affect
role
host
cell
immun
evas
thu
strongli
detriment
parasit
surviv
target
leishmaniadepend
epigenet
host
cell
reprogram
import
impact
intracellular
pathogen
host
cell
transcriptom
incit
studi
epigenet
consequ
infect
epigenet
refer
herit
chang
gene
express
involv
modif
underli
dna
sequenc
depend
alter
either
dna
histon
protein
influenc
chromatin
structur
local
gene
express
variou
pathogen
modul
host
cell
dna
methyl
level
inhibit
express
gene
involv
clearanc
infecti
agent
also
increas
express
gene
promot
microbi
growth
surviv
exampl
chang
dna
methyl
level
link
attenu
proinflammatori
signal
mycobacterium
tuberculosi
infect
modul
inflammatori
respons
apoptosi
pathogeninduc
signal
burkholderia
pseudomallei
infect
chang
host
behavior
observ
toxoplasma
gondiiinfect
mice
decreas
methyl
level
arginin
vasopressin
promot
subsequ
increas
neuron
gene
express
link
fear
revers
natur
predat
promot
parasit
transmiss
contrast
exampl
limit
inform
avail
epigenet
impact
leishmania
infect
host
cell
recent
studi
show
l
donovani
caus
epigenet
variat
macrophag
dna
methyl
thu
interf
gene
implic
host
cell
antimicrobi
defens
infecti
microb
also
remodel
chromatin
access
alter
histon
modif
exampl
gondii
infect
block
histon
phosphoryl
serin
acetyl
lysin
promot
thu
caus
transcript
downregul
proinflammatori
cytokin
likewis
decreas
histon
acetyl
gondii
infect
link
alter
bind
promot
revers
treatment
histon
deacetylas
inhibitor
theileriainduc
methyltransferas
activ
increas
histon
lysin
trimethyl
promot
host
cell
matrix
metalloproteinas
gene
increas
express
protein
link
invas
phenotyp
infect
cell
addit
secret
microbi
protein
shown
interfer
host
epigenet
control
gene
express
influenza
viru
share
similar
tail
bind
human
polymeraseassoci
factor
complex
thu
attenu
antivir
gene
express
listeria
monocytogen
infect
host
deacetylas
sirtuin
transloc
nucleu
caus
deacetyl
therebi
facilit
infect
repress
specif
set
gene
chlamydia
trachomati
legionella
pneumophila
use
similar
mechan
secret
protein
conserv
set
domain
specif
methyl
host
cell
histon
allow
direct
regul
host
gene
express
surprisingli
despit
massiv
effect
leishmania
infect
host
cell
transcriptom
potenti
effect
parasitereleas
proteas
nuclear
proteom
inform
avail
parasit
affect
histon
modif
host
macrophag
leishmania
genom
encod
import
number
put
histonemodifi
enzym
hme
light
larg
constitut
gene
express
earlybranch
eukaryot
interest
specul
protein
may
releas
modifi
host
cell
histon
establish
permiss
condit
intracellular
surviv
altern
leishmania
infect
may
alter
activ
host
cell
hme
establish
epigenet
profil
permiss
intracellular
parasit
surviv
target
parasitereleas
hme
directli
modul
host
cell
epigenom
open
excit
new
avenu
antileishmani
therapi
may
refractori
emerg
drug
resist
possibl
support
recent
find
demonstr
antileishmani
effect
imipramin
antidepress
mediat
via
effect
host
cell
decreas
express
thu
overcom
host
celldepend
mechan
antimoni
resist
conclus
capac
leishmania
evolv
toward
drugresist
phenotyp
call
new
concept
antileishmani
drug
discoveri
review
propos
new
strategi
target
parasit
ectokinas
modul
host
cell
phenotyp
establish
permiss
condit
parasit
surviv
target
host
cell
histonemodifi
enzym
restor
normal
macrophag
transcript
profil
may
deleteri
intracellular
leishmania
surviv
fig
systemslevel
approach
combin
highthroughput
sequenc
proteom
metabolom
analys
rnai
screen
pharmacolog
assess
need
conduct
establish
proofofprincipl
strategi
discov
valid
novel
target
drug
target
direct
genet
control
parasit
may
allow
discoveri
inhibitor
like
refractori
classic
mechan
drug
resist
often
involv
mutat
target
gene
uptak
system
amplif
efflux
pump
despit
great
promis
hostdirect
therapi
bear
new
challeng
first
given
differ
lifestyl
pathogen
major
trypanosomatid
pathogen
brucei
oblig
extracellular
pathogen
cruzi
infect
variou
mammalian
cell
develop
pankinetoplastid
therapi
seem
difficult
fact
illustr
recent
highthroughput
drugscreen
campaign
trypanosomatid
identifi
compound
broad
activ
even
though
one
may
expect
turn
big
pharma
hostdirect
therapi
quit
contrari
strategi
may
actual
incit
import
interest
macrophag
host
cell
variou
viral
bacteri
fungal
pathogen
major
global
public
health
impact
conceiv
pathogen
evolv
intracellular
surviv
strategi
analog
one
employ
leishmania
open
excit
yet
unexplor
possibl
panintracellular
pathogen
therapi
second
major
concern
hostdirect
therapi
toxic
howev
mani
host
function
target
success
therapi
variou
noncommunic
diseas
cancer
autoimmun
repurpos
strategi
alreadi
success
appli
variou
infecti
diseas
exampl
protein
kinas
epigenet
enzym
repres
import
group
drug
target
current
develop
variou
human
diseas
subject
sever
us
food
drug
administr
fda
approv
drug
open
interest
venu
repurpos
exist
treatment
good
safeti
profil
antileishmani
chemotherapi
high
attrit
rate
drug
discoveri
pipelin
leishmanias
mean
new
candid
drug
avail
leishmania
genom
plastic
allow
swift
adapt
new
antiparasit
drug
target
leishmaniahost
cell
interact
novel
strategi
circumv
leishmania
drug
resist
leishmania
ectoprotein
like
refractori
drug
resist
modul
host
cell
epigenom
import
control
intracellular
leishmania
growth
top
five
paper
